Methods and compositions for treating cancers using antisense

a cancer and antisense technology, applied in the field of compositions and methods for treating cancers using antisense, can solve the problems of poor prognosis of malignant glioma, particularly glioblastoma multiforme, and the inability to address the challenges created by solid tumors in immunotherapy trials, and achieve optimal anti-tumor response and inhibit tumor regrowth

Inactive Publication Date: 2018-09-13
THOMAS JEFFERSON UNIV
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite advances in cancer therapy, the prognosis for malignant glioma, particularly glioblastoma multiforme, and many other cancers remains poor.
Immunotherapy trials, although promising in theory, have not addressed the challenges created by solid tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating cancers using antisense
  • Methods and compositions for treating cancers using antisense
  • Methods and compositions for treating cancers using antisense

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0134]Vaccination with Autologous Tumor Cells and IGF-1R AS ODN in Patients with Recurrent Glioblastoma

[0135]Criteria and Study Objective

[0136]Twelve subjects were enrolled for treatment after failure from standard therapy. Each patient met the following criteria: age>18, a Karnofsky performance score of 60 or better, and no co-morbidities that would preclude elective surgical re-resection. The subjects were treated by 24 hour implantation in the rectus sheath of ten biodiffusion chambers containing irradiated autologous tumor cells and IGF-1R AS ODN with the objective of stimulating tumor immunity. Patients were monitored for safety, clinical and radiographic as well as immune responses. Study objectives included assessment of safety and radiographic responses as well as exploratory objectives looking at immune function and response.

TABLE 1Summary of Patients enrolledTimeOriginalLymphocyteIDH-1&IDH-2betweenlymphocytecount atmutation / surgeriesChamberscountenrollmentPreviousMGMTSubje...

example 2

[0185]Vaccination of Newly Diagnosed Subjects with Glioblastoma

[0186]We demonstrated biological effectiveness of the vaccine protocol involving an autologous cell vaccine delivered as part of a formulated combination product involving implanted biodiffusion chambers in patients with recurrent malignant gliomas who had failed standard treatment,

[0187]Example 2 describes responses to administering the vaccine to newly diagnosed glioma patients, including implanting 20 chambers for 24 or 48 hours and 10 chambers for 24 or 48 hours. In each case, 2 μg of NOBEL was added into the chamber prior to irradiation in each case. When compared to standard of care in the first interim analysis, there were significant improvements in both progression-free survival and overall survival (FIG. 9). This was most notably due to the performance of the higher dose cohorts after vaccination. We first noted significantly higher peak and mean interferon-gamma levels after vaccination in the newly diagnosed ...

example 3

Fully Formulated Chambers Have Greater Adjuvanticity

[0189]The fully formulated chamber includes the autologous tumor cells and other cells included in the tumor microenvironment (TME) treated 6 hours prior to implantation with 4 mg / ml of IGF-1R AS ODN. The treated TME is then encapsulated with exogenous addition of at least 2 μg of IGF-1R AS ODN and the chamber is then irradiated with 5 Gy of gamma-irradiation.

[0190]We increased the number of chambers, meaning that the dose of IGF-1R AS ODN received by each patient increased compared to previous studies. For example, twice the number of chambers implanted resulted in twice the amount of the antisense implanted and capable of diffusing out of the chamber, meaning the dose of AS ODN was about 40 μg, split between 20 chambers.

[0191]The antisense sequence, particularly its palindromic CpG motif, and the direct mixture with glioma cells in situ effectively initiate anti-tumor immunity. Notably, the sense sequence with the same palindromi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
wet weight yieldaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application No. 62 / 469,003 filed on Mar. 9, 2017, and 62 / 629,972, filed on Feb. 13, 2018, each entitled “Methods and Compositions for Treating Cancers Using Antisense,” the disclosure of each of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present disclosure relates to compositions and methods for treating cancers using antisense nucleic acids directed against Insulin-like Growth Factor-1 Receptor (IGF-1R). The present disclosure also relates to compositions and methods for treating cancers by treating subjects with at least one implantable irradiated biodiffusion chamber (see U.S. Pat. No. 6,541,036 and PCT / US2016 / 026970, which are incorporated herein by reference in their entireties) comprising tumor cells and an antisense nucleic acid directed against IGF-1R.DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY[0003]The contents of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7105A61P35/00
CPCA61K31/7105A61P35/00G01N33/57484A61K2039/545A61K2039/55561C12N2320/32C12N15/1138A61K31/713C12N2310/11A61K2039/585A61K39/0011A61K39/001103C12N5/0012A61K2039/5152A61K2039/53A61K2039/80A61K2039/572C12N15/11C12N15/52
Inventor ANDREWS, DAVID W.HOOPER, DOUGLAS C.
Owner THOMAS JEFFERSON UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap